On September 12, 2022, Del. Michelle Maldonado and John Newby, CEO of Virginia Bio, welcomed participants to a virtual and in-person legislative briefing on the transformative potential of gene therapies on rare disease. The program aimed to explain the science behind cell and gene therapies, explore their potential to positively impact patients’ lives, and review the policy considerations that will determine how to best promote access to the therapies.
Presenters gathered with in-person participants for a luncheon at the VA Bio+ Tech Park prior to the program. The briefing included remarks from Andrew Krouse, CEO of Slate Bio; Colin Werth, Member of Parent Project Muscular Dystrophy’s Adult Advisory Committee (PAAC); Mark Trusheim, Strategic Director of NEWDIGS; and Patrick Plues, VP of State Government Affairs, BIO.